宫颈癌为妇科常见的恶性肿瘤，其发病年轻化，发病率逐年上升。据统计，本病在发展中国家的发病率以及病死率分别位居女性恶性肿瘤的第二位和第三位，对女性的生命健康造成严重的威胁。大量的流行病学研究发现高危型人乳头瘤病毒持续感染是宫颈癌发生和宫颈癌前病变进展的必要条件。研究发现，从宫颈高危型人乳头瘤病毒持续感染发展至宫颈上皮内瘤变再到宫颈癌约需10年的时间。因此，以HR-HPV在宫颈癌的发生和发展中的关键作用为突破口，加强对HR-HPV的筛检和诊疗，对宫颈癌的预防有至关重要的临床意义。尽管目前的宫颈癌筛查指南日趋完善，但西医对HR-HPV感染的处理主要通过实时监测、密切随访来关注HR-HPV的消退情况，尚缺乏权威、特效的治疗方式。现对近年来中医药治疗宫颈高危型人乳头瘤病毒感染的文献进行综述，探索中医治疗宫颈高危型人乳头瘤病毒感染的临床思路。

Cervical cancer is a common malignant tumor in gynecology, and its incidence is young and the incidence is increasing year by year. According to statistics, the incidence and mortality of this disease in developing countries rank second and third in female malignant tumors, which pose a serious threat to women's life and health. A large number of epidemiological studies have found that persistent infection of high-risk human papillomavirus is a necessary condition for the occurrence of cervical cancer and the progress of cervical precancerous lesions. The study found that it takes about 10 years from persistent cervical high-risk human papillomavirus infection to cervical intraepithelial neoplastic transformation to cervical cancer. Therefore, taking the key role of HR-HPV in the occurrence and development of cervical cancer as a breakthrough, strengthening the screening and diagnosis and treatment of HR-HPV is of great clinical significance for the prevention of cervical cancer. Although the current guidelines for cervical cancer screening are becoming more and more perfect, the management of HR-HPV infection in western medicine is mainly through real-time monitoring and close follow-up to pay attention to the regression of HR-HPV, and there is still a lack of authority and special effect treatment. This paper reviewed the literature on the treatment of cervical high risk human papillomavirus infection with traditional Chinese medicine in recent years, and explored the clinical thinking of traditional Chinese medicine in the treatment of uterine high risk human foramen head tumor virus infection.

补充立项部门重庆市科卫联合中医药科研项目（2020ZY024101）：扶正清毒化瘀法防治宫颈HSIL患者锥切术后不良转归的临床研究，负责人：罗梅。